SCPS

Scopus BioPharma Inc. [SCPS] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

SCPS Stock Summary

In the News

08:30 08 Jun 2023 SCPS

Scopus BioPharma's Subsidiary — Duet BioTherapeutics — to Present at the 3rd Annual STING & TLR-Targeting Therapies Summit

Alan Horsager, Ph.D., President and Chief Executive Officer of Duet, to Present on TLR9 Activation and STAT3 Inhibition: A Bifunctional Approach to Immuno-Oncology

05:30 08 Jun 2023 SCPS

Scopus BioPharma Announces Adjournment of Annual Meeting of Stockholders

NEW YORK, Oct. 08, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, today announced that, on October 8, 2021, its 2021 Annual Meeting of Stockholders (the “Annual Meeting”) was adjourned to 1:00 p.m., Eastern time, on Friday, November 5, 2021, without any business being conducted, pursuant to a Stipulation and Court Order approved by the Delaware Court of Chancery between Scopus and Morris C. Laster, M.D. in connection with Dr. Laster's pending claims against Scopus in the Delaware Court of Chancery. Notwithstanding the Stipulation and Court Order requiring Dr. Laster to cause all shares of Scopus common stock held by him to be present in person or by proxy at the Annual Meeting and any adjournments thereof exclusively for the purposes of establishing a quorum at the meeting, Dr. Laster failed to satisfy this requirement by both not attending the Annual Meeting in person and not making his shares present by proxy.

08:45 08 Jun 2023 SCPS

Scopus BioPharma to Present at the LD Micro Main Event

Scopus to present on the recent launch of Duet Therapeutics,  its wholly-owned subsidiary focused on immuno-oncology

04:30 08 Jun 2023 SCPS

Scopus BioPharma Retaining Counsel to Investigate Unusual Market Activity

NEW YORK, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”), a clinical-stage biopharmaceutical company, announced today that it is retaining Boies Schiller Flexner LLP to conduct a market manipulation investigation.

07:00 08 Jun 2023 SCPS

Scopus BioPharma to Present at MicroCap Rodeo's Fall Harvest Best Ideas Conference

Scopus to present on the recent launch of Duet Therapeutics,  its wholly-owned subsidiary focused on immuno-oncology

08:30 08 Jun 2023 SCPS

Scopus BioPharma's Subsidiary — Duet Therapeutics — Announces Release of Preclinical Data Being Presented at 17th Annual Meeting of the Oligonucleotide Therapeutics Society

Data from two different studies benchmark Duet's proprietary bifunctional oligonucleotides against immune checkpoint inhibitors (“Checkpoint Inhibitors”) in lymphoma and prostate tumor models in mice

09:15 08 Jun 2023 SCPS

Scopus BioPharma's Subsidiary Duet Therapeutics Set to Release Scientific Data During the 17th Annual Meeting of the Oligonucleotide Therapeutics Society

Duet releases video depicting mechanism of action for its proprietary CpG-STAT3 inhibitors to coincide with Duet presentations at OTS Meeting Duet releases video depicting mechanism of action for its proprietary CpG-STAT3 inhibitors to coincide with Duet presentations at OTS Meeting

06:30 08 Jun 2023 SCPS

Scopus BioPharma's Subsidiary — Duet Therapeutics — Set to Release Scientific Data During the 17th Annual Meeting of the Oligonucleotide Therapeutics Society

Duet releases video depicting mechanism of action for its proprietary CpG-STAT3 inhibitors to coincide with Duet presentations at OTS Meeting Duet releases video depicting mechanism of action for its proprietary CpG-STAT3 inhibitors to coincide with Duet presentations at OTS Meeting

06:00 08 Jun 2023 SCPS

Scopus BioPharma to Adjourn 2021 Annual Meeting of Stockholders

NEW YORK, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, announced today that, pursuant to a stipulation with Morris C. Laster, M.D. in connection with pending claims brought by Dr. Laster in the Delaware Court of Chancery, the company intends to convene, and then immediately adjourn, the company's scheduled October 8, 2021 Annual Meeting of Stockholders (the “Annual Meeting”) such that the Annual Meeting will be held and the vote on the items of business to be considered at the Annual Meeting will be taken no earlier than 14 days after a decision on the merits or a final settlement between the parties. The company and Dr. Laster intend to conduct discussions in an effort to seek to resolve the disputes between the parties and have also agreed to an expedited timeline for resolving the Delaware court action.

08:30 08 Jun 2023 SCPS

Scopus BioPharma's Subsidiary — Duet Therapeutics — to Present at the 17th Annual Meeting of the Oligonucleotide Therapeutics Society

Alan Horsager, Ph.D., President and Chief Executive Officer of Duet Therapeutics, will present on CpG-STAT3 RNA Silencing and Antisense inhibitors

SCPS Financial details

Company Rating
Neutral
Market Cap
1.99M
Income
-9.4M
Revenue
0
Book val./share
-0.23
Cash/share
0.05
Dividend
-
Dividend %
-
Employees
13
Optionable
No
Shortable
Yes
Earnings
12 May 2023
P/E
-0.25
Forward P/E
-
PEG
0.03
P/S
-
P/B
-0.34
P/C
1.02
P/FCF
-0.48
Quick Ratio
0.15
Current Ratio
0.17
Debt / Equity
-1.34
LT Debt / Equity
-
-
-
EPS (TTM)
-0.41
EPS next Y
-
EPS next Q
-
EPS this Y
-63.82%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-1.71%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
0%
Inst Trans
-0.36%
ROA
-586%
ROE
166%
ROC
1.26%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
39.78M
Shs Float
30.52M
-
-
-
-
Target Price
-
52W Range
0.04-0.579
52W High
-
52W Low
-
RSI
48
Rel Volume
0.04
Avg Volume
13.1K
Volume
508
Perf Week
2%
Perf Month
-15.52%
Perf Quarter
-37.04%
Perf Half Y
-75.83%
-
-
-
-
Beta
1.60031
-
-
Volatility
0.01%, 0.01%
Prev Close
-33.9%
Price
0.051
Change
2%

SCPS Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2018-12-312019-12-312020-12-312021-12-31 2022-12-31
Revenue per share
00000
Net income per share
-0.05-0.18-0.87-1.52-0.55
Operating cash flow per share
-0.05-0.14-0.19-0.66-0.39
Free cash flow per share
-0.05-0.14-0.19-0.66-0.39
Cash per share
000.140.460.01
Book value per share
0-0.01-0.140.23-0.31
Tangible book value per share
0-0.01-0.140.23-0.33
Share holders equity per share
0-0.01-0.140.23-0.31
Interest debt per share
000.220.040
Market cap
88.66M88.66M198.31M28.21M2.06M
Enterprise value
88.65M88.62M198.76M20.26M1.93M
P/E ratio
-129.24-32.96-17.14-1.07-0.18
Price to sales ratio
00000
POCF ratio
-118.63-41.81-78.53-2.47-0.25
PFCF ratio
-118.63-41.73-78.53-2.47-0.25
P/B Ratio
-16.65K-1.07K-108.297.02-0.31
PTB ratio
-16.65K-1.07K-108.297.02-0.31
EV to sales
00000
Enterprise value over EBITDA
-129.24-32.95-19.57-0.73-0.16
EV to operating cash flow
-118.63-41.79-78.71-1.77-0.24
EV to free cash flow
-118.63-41.71-78.71-1.77-0.24
Earnings yield
-0.01-0.03-0.06-0.93-5.64
Free cash flow yield
-0.01-0.02-0.01-0.41-3.95
Debt to equity
-25.9-10.31-2.081.04-1.14
Debt to assets
1.041.111.930.5119
Net debt to EBITDA
00.01-0.040.290.01
Current ratio
0.960.90.521.960.05
Interest coverage
00-14.38-35.670
Income quality
1.090.790.230.420.69
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
00000
Capex to revenue
00000
Capex to depreciation
0-6.40-1.33-0.9
Stock based compensation to revenue
00000
Graham number
0.020.151.632.821.96
ROIC
-5.3-3.856.43.5-81.12
Return on tangible assets
-5.17-3.49-5.86-3.21-29.6
Graham Net
-0.01-0.05-0.150.22-0.35
Working capital
-5.33K-86.52K-1.83M4.01M-7.06M
Tangible asset value
-5.33K-82.86K-1.83M4.02M-7.06M
Net current asset value
-5.33K-86.52K-1.83M4.01M-7.06M
Invested capital
00-1.2500
Average receivables
41.26K14.21K28100
Average payables
00000
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
128.832.466.32-6.541.77
Capex per share
00000

Quarterly Fundamentals Overview

Last date of statement is 2023-03-31 for Q1

Metric History 2022-03-312022-06-302022-09-302022-12-31 2023-03-31
Revenue per share
00000
Net income per share
-0.22-0.16-0.09-0.08-0.08
Operating cash flow per share
-0.19-0.14-0.04-0.02-0.03
Free cash flow per share
-0.19-0.14-0.04-0.09-0.03
Cash per share
0.190.050.010.010.05
Book value per share
-0.03-0.18-0.26-0.31-0.23
Tangible book value per share
-0.03-0.18-0.26-0.33-0.25
Share holders equity per share
-0.03-0.18-0.26-0.31-0.23
Interest debt per share
00000
Market cap
14.58M9.07M5.11M2.06M1.84M
Enterprise value
10.6M7.91M4.8M1.93M443.48K
P/E ratio
-0.78-0.68-0.67-0.3-0.19
Price to sales ratio
00000
POCF ratio
-3.67-3.15-6-4.87-2.43
PFCF ratio
-3.66-3.15-6-1.04-2.43
P/B Ratio
-27.48-2.45-0.93-0.31-0.27
PTB ratio
-27.48-2.45-0.93-0.31-0.27
EV to sales
00000
Enterprise value over EBITDA
-2.28-2.38-2.53-1.05-0.17
EV to operating cash flow
-2.67-2.75-5.63-4.58-0.58
EV to free cash flow
-2.66-2.75-5.63-0.98-0.58
Earnings yield
-0.32-0.37-0.37-0.84-1.33
Free cash flow yield
-0.27-0.32-0.17-0.96-0.41
Debt to equity
-9.69-1.45-1.08-1.14-1.34
Debt to assets
1.123.2114.24195.81
Net debt to EBITDA
0.850.350.160.070.52
Current ratio
0.90.310.070.050.17
Interest coverage
00000
Income quality
0.850.870.450.230.28
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
0003.670
Capex to revenue
00000
Capex to depreciation
-2.5500-6.71K0
Stock based compensation to revenue
00000
Graham number
0.350.790.730.760.64
ROIC
1.390.559.22-12.092.04
Return on tangible assets
-1.01-1.98-4.57-4.41-1.53
Graham Net
-0.06-0.2-0.27-0.35-0.26
Working capital
-533.84K-3.7M-5.51M-7.06M-7.71M
Tangible asset value
-530.43K-3.7M-5.5M-7.06M-7.71M
Net current asset value
-533.84K-3.7M-5.51M-7.06M-7.71M
Invested capital
00000
Average receivables
00000
Average payables
02.69M2.69M00
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
8.790.90.340.260.35
Capex per share
000-0.070

SCPS Frequently Asked Questions

What is Scopus BioPharma Inc. stock symbol ?

Scopus BioPharma Inc. is a US stock , located in New york of Ny and trading under the symbol SCPS

What is Scopus BioPharma Inc. stock quote today ?

Scopus BioPharma Inc. stock price is $0.051 today.

Is Scopus BioPharma Inc. stock public?

Yes, Scopus BioPharma Inc. is a publicly traded company.

Something similar

Top by Market Cap
Same Sector
Same Price Range
Similar Market Cap